BridgeMD
Compares treatment options for Lymphoma
Official title Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
ClinicalTrials.gov ID: NCT07270263
What this study is testing
What is Apixaban?
Apixaban is an investigational medicine, given as an once-daily injection under the skin, being studied as a potential treatment for lymphoma.
Also referred to as Eliquis, Poltixa.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study investigates the efficacy and safety of direct oral anticoagulants (DOACs) in comparison with standard low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in patients with hematological malignancies. Eligible participants will be randomized to receive reduced-dose apixaban, reduced-dose rivaroxaban, or standard-dose LMWH.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Active hematologic malignancy at the time of initiation of systemic therapy, including multiple myeloma, myeloproliferative neoplasm, lymphoma or...
- Use of anticoagulant agents for primary thromboprophylaxis, including direct oral anticoagulants (DOACs) at reduced doses (apixaban 2.5 mg twice...
You likely can't join if
- Major bleeding within the last month (including gastrointestinal or intracranial bleeding).
- Active major bleeding.
- Hemoglobin concentration \< 8 g/dL.
- Thrombocytopenia with platelet count \<30 × 10⁹/L.
- ECOG performance status of 3 or 4.
- Expected survival \<6 months.
See the full eligibility criteria
- Active hematologic malignancy at the time of initiation of systemic therapy, including multiple myeloma, myeloproliferative neoplasm, lymphoma or other hematologic cancer with a Khorana score ≥ 2 points (intermediate or...
- Use of anticoagulant agents for primary thromboprophylaxis, including direct oral anticoagulants (DOACs) at reduced doses (apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily) or low-molecular-weight heparin...
- Major bleeding within the last month (including gastrointestinal or intracranial bleeding).
- Active major bleeding.
- Hemoglobin concentration \< 8 g/dL.
- Thrombocytopenia with platelet count \<30 × 10⁹/L.
- ECOG performance status of 3 or 4.
- Expected survival \<6 months.
- History of mechanical heart valve or severe mitral stenosis.
- Estimated glomerular filtration rate (eGFR) \< 25 mL/min.
- Hepatic impairment (ALT ≥ 3× upper limit of normal or bilirubin ≥ 2× upper limit of normal).
- Acute coronary syndrome or ischemic stroke within the last 6 months.
- Anticipated significant drug-drug interactions between DOACs and anticancer agents.
- Known antiphospholipid syndrome (APS).
The study team makes the final eligibility decision.
Where it's taking place
- Gdansk, Pomeranian Voivodeship, Poland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Gdansk, Pomeranian Voivodeship, Poland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.